The gonadotropin-releasing hormone antagonist protocol - The protocol of choice for the polycystic ovary syndrome patient undergoing controlled ovarian stimulation

Acta Obstetricia et Gynecologica Scandinavica

Volumn 91, Issue 6, 2012, Pages 643-647

  Kol, Shahar ^a   Homburg, Roy ^b,c   Alsbjerg, Birgit ^d   Humaidan, Peter ^e  

^a RAMBAM MEDICAL CENTER   (Israel)

^b BARZILAI MEDICAL CENTER   (Israel)

^c HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^d SKIVE REGIONAL HOSPITAL   (Denmark)

^e ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

controlled ovarian stimulation; gonadotropin releasing hormone agonist; gonadotropin releasing hormone antagonist; in vitro fertilization; ovarian hyperstimulation syndrome; Polycystic ovary syndrome

Indexed keywords

CHORIONIC GONADOTROPIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE;

EMBRYO TRANSFER; FERTILIZATION IN VITRO; FREEZE THAWING; HIGH RISK PATIENT; HUMAN; INCIDENCE; LUTEAL PHASE; OOCYTE MATURATION; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

CHORIONIC GONADOTROPIN; CRYOPRESERVATION; EMBRYO IMPLANTATION; EMBRYO TRANSFER; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; INFERTILITY, FEMALE; LUTEAL PHASE; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME;

EID: 84862108428     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1111/j.1600-0412.2012.01399.x     Document Type: Review

References (33)

1. Al-Inany HG, Abou-Setta AM, Aboulghar M,. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online. 2007; 14: 640-9.
2. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G,. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update. 2006; 12: 651-71. (Pubitemid 44605507)
3. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, et al,. GnRH antagonists are safer than agonists: an update of a Cochrane review. Hum Reprod Update. 2011; 17: 435.
4. Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y,. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 2012; 24: 6-22.
5. Gonen Y, Balakier H, Powell W, Casper RF,. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990; 71: 918-22.
6. Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O,. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009; 91: 365-71.
7. Bodri D, Guillen JJ, Trullenque M, Schwenn K, Esteve C, Coll O,. Early ovarian hyperstimulation syndrome is completely prevented by gonadotropin releasing-hormone agonist triggering in high-risk oocyte donor cycles: a prospective, luteal-phase follow-up study. Fertil Steril. 2010; 93: 2418-20.
8. Galindo A, Bodri D, Guillén JJ, Colodrón M, Vernaeve V, Coll O,. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol. 2009; 25: 60-6.
9. Hernández ER, Gómez-Palomares JL, Ricciarelli E,. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertil Steril. 2009; 91 (4 Suppl): 1358-61.
10. Manzanares MA, Gómez-Palomares JL, Ricciarelli E, Hernandez ER,. Triggering ovulation with gonadotropin-releasing hormone agonist in in vitro fertilization patients with polycystic ovaries does not cause ovarian hyperstimulation syndrome despite very high estradiol levels. Fertil Steril. 2010; 93: 1215-9.
11. Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM,. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online. 2006; 13: 628-38. (Pubitemid 44760885)
12. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, et al,. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod. 2004; 19: 1993-2000.
13. Kolibianakis E, Zikopoulos K, Albano C, Camus M, Tournaye H, Van Steirteghem A, et al,. Reproductive outcome of polycystic ovarian syndrome patients treated with GnRH antagonists and recombinant FSH for IVF/ICSI. Reprod Biomed Online. 2003; 7: 313-8. (Pubitemid 37259284)
14. Kurzawa R, Ciepiela P, Baczkowski T, Safranow K, Brelik P,. Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study. J Assist Reprod Genet. 2008; 25: 365-74.
15. Humaidan P, Kol S, Papanikolaou EG,. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update. 2011; 17: 510-524.
16. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernández ER,. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006; 86: 1682-7. (Pubitemid 44781379)
17. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C,. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008; 89: 84-91.
18. Swanton A, Storey L, McVeigh E, Child T,. IVF outcome in women with PCOS, PCO and normal ovarian morphology. Eur J Obstet Gynecol Reprod Biol. 2010; 149: 68-71.
19. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, et al,. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod. 2005; 20: 636-41. (Pubitemid 40425488)
20. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grøndahl ML, Westergaard L, et al,. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod. 2005; 20: 1213-20. (Pubitemid 40796107)
21. Humaidan P, Bungum L, Bungum M, Yding AC,. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online. 2006; 13: 173-8. (Pubitemid 44207763)
22. Humaidan P,. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online. 2009; 18: 630-4.
23. Humaidan P, Ejdrup BH, Westergaard LG, Yding AC,. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril. 2010; 93: 847-54.
24. Humaidan P, Westergaard LG, Mikkelsen AL, Fukuda M, Yding AC,. Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. Fertil Steril. 2011; 95: 2034-8.
25. Pirard C, Donnez J, Loumaye E,. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod. 2006; 21: 1894-900. (Pubitemid 44028266)
26. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H,. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril. 2011; 95: 1174-7.
27. Radesic B, Tremellen K,. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod. 2011; 26: 3437-42.
28. Youssef MA, Van der Veen F, Al-Inany HG, Griesinger G, Mochtar MH, Aboulfoutouh I, et al,. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles. Cochrane Database Syst Rev. 2011; (1):CD008046.
29. Humaidan P, Kol S, Engmann L, Benadiva C, Papanikolaou EG, Andersen CY,. Should Cochrane reviews be performed during the development of new concepts? Hum Reprod. 2012; 27: 6-8.
30. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C,. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. Fertil Steril. 2011; 95: 2715-7.
31. Griesinger G, Kolibianakis EM, Papanikolaou EG, Diedrich K, Van Steirteghem A, Devroey P, et al,. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil Steril. 2007; 88: 616-21. (Pubitemid 47368245)
32. Melo M, Busso CE, Bellver J, Alama P, Garrido N, Meseguer M, et al,. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study. Reprod Biomed Online. 2009; 19: 486-92.
33. Cerrillo M, Rodriguez S, Mayoral M, Pacheco A, Martinez-Salazar J, Garcia-Velasco JA,. Differential regulation of VEGF after final oocyte maturation with GnRH agonist versus hCG: a rationale for OHSS reduction. Fertil Steril. 2009; 91 (4 Suppl): 1526-8.